Company Overview and News

 
IPO market to pick up pace

17h thestar.com.my
Generating excitement: According to CIMB Research, Etiqa’s potential listing is expected to garner a market capitalisation of between RM5.3bil and RM10.7bil upon listing, based on a priceto-book value of between of 1.4 and 2.8 times.
Upvote Downvote

 
Three-pronged approach for Axiata

18h thestar.com.my
JUST like how the cellular telecommunications industry is changing, Axiata Group Bhd , the regional telecoms company, is looking at a three-pronged approach towards driving its business.
Upvote Downvote

 
Maybank shares higher on potential Etiqa listing

2018-04-19 themalaymailonline
Maybank's shares edge up as it prepares to spinoff its Etiqa insurance arm. — File pic KUALA LUMPUR, April 19 — Malayan Banking Bhd’s (Maybank) share price advanced two sen in early trade as the country’s biggest bank is preparing to spin off and list its Etiqa insurance arm on the local stock exchange.
Upvote Downvote

 
Maybank prepares to spin off, list insurance unit

2018-04-19 thestar.com.my
Listing candidate: Customers using ATMs at Maybank headquarters. Maybank’s insurance unit Etiqa is estimated to be worth at least RM3.89bil.
Upvote Downvote

 
Maybank preparing to spin off insurance unit, sources say

2018-04-18 themalaymailonline
A pedestrian walks past a Maybank Bhd bank branch in Jalan Medan Tunku, Kuala Lumpur January 4, 2018. — Picture by Firdaus LatifKUALA LUMPUR, April 18 — Malayan Banking Bhd (Maybank), Malaysia’s biggest bank, is preparing to spin off and list its Etiqa insurance arm on the local stock exchange, sources with knowledge of the matter said today.
Upvote Downvote

 
Maybank sees online transactions increasing to 6.4 billion this year

2018-04-18 thestar.com.my
(From left) Maybank head of virtual banking and payments Kalyani Nair, group chief technology officer Mohd Suhail Amar Suresh, head of group community financial services Datuk Lim Hong Tat, group chief strategy officer Michael Foong, and head of community financial services Malaysia Datuk Hamirullah Boorhan at the launch of the new and reimagined internet banking platform Maybank2u.
Upvote Downvote

 
Maybank: Online transactions to hit 6.4 billion this year

2018-04-17 themalaymailonline
The new Maybank2u website comes with a complete change of user interface with new features that will provide users with more convenience when conducting transactions online. — Picture by Ahmad ZamzahuriKUALA LUMPUR, April 17 — Malayan Banking Bhd (Maybank) expects the number of its online banking transactions in Malaysia to increase to 6.4 billion in 2018, aided by the new Maybank2u website which will be launched this Thursday.
Upvote Downvote

 
Maybank: Online transactions to hit 6.4b this year

2018-04-17 themalaymailonline
The new Maybank2u website comes with a complete change of user interface with new features that will provide users with more convenience when conducting transactions online. — Picture by Ahmad ZamzahuriKUALA LUMPUR, April 17 — Malayan Banking Bhd (Maybank) expects the number of its online banking transactions in Malaysia to increase to 6.4 billion in 2018, aided by the new Maybank2u website which will be launched this Thursday.
Upvote Downvote

 
Investors Are Taking Nothing for Granted About Malaysia’s Election - Bloomberg

2018-04-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Funds take nothing for granted in Malaysia vote as ringgit halts

2018-04-16 themalaymailonline
PKR and Barisan Nasional flags are seen erected along a road in Ipoh April 11, 2018. — Picture by Farhan NajibKUALA LUMPUR, April 16 — Polls predict Malaysian Prime Minister Datuk Seri Najib Razak will be returned to office in next month’s general election but a string of political shocks around the world in recent years mean investors are bracing for a range of possible outcomes.
Upvote Downvote

 
Staying the course

2018-04-14 thestar.com.my
Mak: Our group wholesale banking practice however looks at clients holistically, based on their longer-term potential – not just in fair weather. Time will tell if our strategy has been correct.
Upvote Downvote

 
Maybank sees another record year ahead

2018-04-12 thestar.com.my
Abdul Farid: We will be disciplined in managing our net interest margins, especially in a rising interest rate environment.
Upvote Downvote

 
With minor exposure, Maybank expects small impact from US-China trade war

2018-04-12 themalaymailonline
A man walks past a Maybank branch at the Dayabumi Complex in Kuala Lumpur, March 30, 2015. — Picture by Yusof Mat Isa KUALA LUMPUR, April 12 — Malayan Banking Bhd (Maybank) said today it is unlikely impacted by the impending United States-China trade war, as it only has three per cent of total exposure to trade in China’s economy.
Upvote Downvote

 
Splash files suit against Syabas to claim RM4.2bil

2018-04-09 thestar.com.my
PETALING JAYA: Syarikat Pengeluar Air Sungai Selangor Sdn Bhd (Splash), an associate company of Gamuda Bhd , has launched legal proceedings against Syarikat Bekalan Air Selangor Sdn Bhd (Syabas) to claim RM4.2bil in outstanding receivables.
Upvote Downvote

 
SPLASH serves writ, statement of claim on Syabas

2018-04-09 themalaymailonline
KUALA LUMPUR, April 9 — Syarikat Pengeluar Air Sungai Selangor Sdn Bhd (SPLASH) has served a writ, together with a statement of claim, on Syarikat Bekalan Air Selangor Sdn Bhd (Syabas), claiming all outstanding receivables owed by SYABAS which amounted to RM4.22 billion.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 56108H105